There was an increase in use of neuraxial anesthesia and peripheral nerve block analgesia rather than general anesthesia for hip fracture procedures.

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Ustekinumab is associated with a higher rate of clinical remission at 6 months compared with anti-TNF therapy among patients with CLDP. Ustekinumab may be more effective than anti-tumor necrosis ...